World’s second largest API company to be created by Sanofi

pharmafile | February 25, 2020 | News story | Manufacturing and Production API, APIs, China API, Coronavirus API, India API, Sanofi 

Sanofi plans to create a new company in Europe dedicated to the production and marketing of active pharmaceutical ingredients (API).

This news comes amidst the coronavirus outbreak, which is threatening the global drug production line due to many countries importing APIs from China.

This new entity will help balance Europe’s reliance on these Chinese and Indian API imports. It would consist of Sanofi combining its European API production sites in Italy, Germany, the UK, Hungary and two others in France. When created, it would rank as the second largest API company in the world with a predicted $1 billion in sales by 2022. Sanofi would hold a 30% stake in the new company and intends it to be debt free to maximise its investment capacities.

Commenting on the plans, Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi, said: “Based on the expertise and experience built over decades within our industrial network, this new entity would help ensure a greater stability in supplying drugs to millions of patients in Europe and beyond. With this endeavour, this new entity would be agile as a standalone company, and able to unlock its growth potential, especially in capturing new third-party sales and all the opportunities of a market growing at a pace of 6% per year.”

Conor Kavanagh


Related Content


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Latest content